Sanofi PT receives Investment Bank Analyst Rating Update
By Scott Kanowsky Investing.com -- Sanofi SA (EPA:SASY) shares slid on Wednesday after the French drugmaker announced that it will halt trials of a new treatment for patients...
Traders await US economic data to justify strongest monthly stock advance in 3 decades Oil rebound slows Bitcoin close to all-time high Key EventsThe most powerful global, monthly...
Earlier this month, the Office for National Statistics (ONS) officially declared the UK economy in recession. It marked the first time since the 2008-09 financial crisis that the...
Shares of Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. REGN gained after it announced the initiation of late-stage studies on experimental coronavirus candidate,...
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
|Average||108.38 (+39.74% Upside)|
|No. of Analysts||26|